On September 30, 2026, Cingulate Inc. announced the appointment of Matthew N. Brams as Executive Vice President and Chief Medical Officer, following the amendment of his employment agreement
Company Information
Company
Cingulate
Location
Kansas City, Missouri, United States
About
Cingulate® is a biopharmaceutical company utilizing its innovative Precision Timed Release™ (PTR) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products.
We aim to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes.
With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), we believe there are multiple therapeutic areas where our PTR technology may be employed to develop additional product candidates, notably anxiety disorders.
Fundz sees it the moment Cingulate changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Kansas CityBiotechnologyHealthcareHealth CarePharmaceuticalBiopharma